InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,954.40
(
-0.52%
)
US TECH 100
20,344.80
(
-0.71%
)
Dow Jones
43,764.00
(
-0.44%
)
Brent Oil
72.28
(
0.58%
)
Bitcoin
88,485.92
(
-2.30%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

wrkingcapital

Send PM Follow Ignore
Followers 0
Posts 59
Boards Moderated 0
Alias Born 08/31/2010

wrkingcapital

Re: BTH post# 3355

Tuesday, 11/16/2010 1:00:05 PM

Tuesday, November 16, 2010 1:00:05 PM

Post# of 80490
Reviewed the report of the second interim analysis of RIDA by the DMC. I noted that in the press release it says:

The DMC advises the sponsor regarding the continuing safety of trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial. According to the study protocol, the DMC is responsible for undertaking the two interim efficacy analyses.

Does this mean that the 3rd and final analyses is in Mercks hands and not the DMC's...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up